

**Announcement No. 15/2010
30 November 2010****Notification of proxies received by the Board of Directors**

Pursuant to section 29 of the Danish Securities Trading Act, cf. section 4(viii), cf. section 5(3), of the executive order on major shareholders, Coloplast A/S announces that the company's Board of Directors has received proxies from a number of shareholders to vote on their behalf at the annual general meeting to be held on 1 December 2010.

Coloplast's Board of Directors has received proxies as a result of which the Board of Directors has at its disposal votes equivalent to more than 5% of the total voting rights at the annual general meeting.

Accordingly, as of today, the Board of Directors has proxies in respect of 8.41% of the voting rights and of the company's total share capital.

After the close of the annual general meeting on 1 December 2010, the Board of Directors' authority to vote under the proxies received will lapse.

Lene Skole
Executive Vice President, CFO

For further information, please contact

Investors and analysts

Lene Skole
Executive Vice President, CFO
Tel. +45 4911 1700

Ian S.E. Christensen
Director of Investor Relations
Tel. +45 4911 1800/+45 4911 1301
Email: dkisec@coloplast.com

Henrik Nord
Investor Relations Manager
Tel. +45 4911 1800/+45 4911 3108
Email: dkhno@coloplast.com

Press and the media

Ulla Lundhus
Media Relations Manager
Tel. +45 4911 1929
Email: dkul@coloplast.com

This announcement is available in a Danish and an English-language version.
In the event of discrepancies, the Danish version shall prevail.

The Coloplast logo is a registered trademark of Coloplast A/S. © 2010-11 All rights reserved. Coloplast A/S, 3050 Humlebæk, Denmark.

Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. We call this intimate healthcare.

Our business includes Ostomy Care, Urology and Continence Care and Wound and Skin Care. We operate globally and employ more than 7,000 people.